AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.
The Wall Street Journal reports that 44% of dermatologists and plastic surgeons polled in a Sanford Bernstein survey said they would consider Botox alternatives if Allergan becomes a Valeant subsidiary.
CEO Severin Schwan tells Reuters that the Swiss firm will be looking for small acquisitions and partnerships.
Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.
The deal includes a $1.6-billion fee if AbbVie tries to walk away.
Salix Pharmaceuticals joins the tax-inversion migration by purchasing Cosmo Technologies.
Allergan's latest pipeline news was a mix of the good and the bad. The good: a potential Lucentis competitor is progressing. The bad: migraine medication Semprana has stalled.
IMS is offering $520 million cash to add Cegedim's CRM and strategic data business. Cegedim says it will use the money to pay down debt.
Dublin-based Shire is urging shareholders to back independence and ignore AbbVie's $46.4 billion bid.
The deal makes Medtronic the most recent company to seek out lower tax rates.
CEO David Pyott told Modern Healthcare that acquisition fallout would have probably included a pinched R&D budget and higher product prices.
The company is buying Genia Technologies for $125 million.
In addition to raising its bid for Allergan, Valeant is lobbying for a shareholder meeting to oust six board members.
The new offer is $49.4 billion.
Pfizer announced Monday that it will no longer pursue AstraZeneca, but industry watchers note it may not really be over.
Pfizer and AstraZeneca present their cases for and against a possible merger to UK lawmakers this week.
Reports indicate Allergan's reported attempt to lure Sanofi and J&J into an partnership have failed, and that the Botox manufacturer has told Valeant to keep its takeover offer to itself.
The firm laid out reasons for why it should remain independent of Pfizer, but analysts say projected earnings are a bit too optimistic and could be a ploy to up the offer.
The $14.2-billion deal is expected to close in the second half of this year.
CEO Ian Read told investors Monday that an AZ merger would benefit Astra shareholders and add oomph to its marketing potential. Another exec said he could "envision" filing palbociclib this year, but made no promises.
Insider-trading allegations have temporarily stopped the merger.
Bloomberg says the Botox manufacturer has reached out to Sanofi and Johnson & Johnson.
The three drugmakers rearranged part of the pharma universe Tuesday with a string of pipeline-altering deals.
The deal would bring Allergan's Botox and Juvederm under the same roof as Restylane.
The rumored $101 billion bid would give Pfizer a foothold in imuno-oncology and diabetes.
The Swiss drugmaker has scooped up Oryzon's experimental acute myeloid leukemia treatment and private Massachusetts diagnostics firm IQuum.
Bloomberg reports that Teva has sparked interest as a takeover target.
The drugmaker, hitherto known for its generic expertise, says the purchase could mean that half its future revenue will come from branded, specialty drugs.
The drugmaker's purchase of private biotech CoStim Pharmaceuticals comes with a host of experimental immuno-oncology agents.
The three drugmakers launched into a series of sell-offs and acquisitions over the weekend.